	Pivotal has announced that it will provide specialized clinical research services in a clinical trial to study the efficacy and safety of hyperimmune plasma in the treatment of hospitalized patients with COVID-19. The two-phase study is a multicenter, randomized, sequential and adaptive design clinical trial that will use the plasma extracted from about 200 convalescent patients with COVID-19 to treat patients in the acute phase of this disease, compared with standard treatment. 

	For more information on the study, click 